An anti-competitive tactic used by brand-name drugmakers called product hopping costs the U.S. healthcare system at least $4.7 billion annually, according to a study from Matrix Global Advisors.
The study — released Sept. 1 from the Washington, D.C.-based economic policy consulting firm and commissioned by the Coalition for Affordable Prescription Drugs — studied the effects of product hopping on the U.S. healthcare system.
Product hopping occurs when a brand-name drugmaker moves patients to a reformulated version of a drug when an existing drug’s patent is set to expire.
Just five instances of product hopping cost the U.S. healthcare system $4.7 billion annually, the study found. It looked at instances of product hopping for the brand-name drugs Prilosec, TriCor, Suboxone, Doryx and Namenda.
Brand-name drugmakers use product hopping to preserve monopolies and prevent generic competition, the study said. Generic drug savings can’t be realized if patients have been moved to a drug that is protected by patents before generic competitors can enter the market.
Find the full study here.
More articles on pharmacy:
Gilead expands oncology portfolio, acquires Immunomedics for $21B
8 considerations to take when preparing for COVID-19 vaccine distribution
‘We’re not finished with remdesivir’: Gilead CEO says trials underway for inhaled version, outpatient IV version
© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.